Evidence map›Paper›PMID 38549519›Full record

SynthesisReviews on recent clinical trials2024

Primary Paraganglioma of the Prostate: A Systematic Review of the Literature for A Rare Entity.

Ilias Giannakodimos, Afroditi Ziogou, Alexios Giannakodimos, Evangelia Mitakidi, Konstantinos Tzelepis, Evangelos Fragkiadis, Nikolaos Charalampakis

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Reviews on recent clinical trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ilias GiannakodimosDepartment of Urology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0003-2267-8464
Afroditi ZiogouDepartment of Medical Oncology, Metaxa Cancer Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0009-0008-5853-5522
Alexios GiannakodimosDepartment of Medical Oncology, Metaxa Cancer Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Evangelia MitakidiDepartment of Urology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Konstantinos TzelepisDepartment of Urology, Geniko Kratiko Nikaias General Hospital, Athens, National and Kapodistrian University of Athens, Athens, Greece.
Evangelos FragkiadisDepartment of Urology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos CharalampakisDepartment of Medical Oncology, Metaxa Cancer Hospital, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParagangliomas of the urinary tract are exceptionally uncommon, and sporadic case reports of primary paraganglioma of the prostate have been reported in the literature.

methodsSystematic research in PubMed/Medline and Scopus databases concerning primary prostatic paraganglioma was performed by two independent investigators.

resultsThis analysis included 25 adult males, with a mean age of 49.8 ± 22.4 years. 32% of included patients had a history of hypertension. Problems during urination (52%), blood loss (44%), either as hematuria or hemospermia, and catecholamine-related symptoms (36%) comprised the most frequently reported clinical manifestations. Digital rectal examination found a palpable nodule in 36% of patients, while prostatic specific antigen (PSA) was normal in all tested patients. Abdominal ultrasound (44%), computed tomography (44%) and magnetic resonance imaging (28%) helped to identify the primary lesion. 24-hour urine epinephrine, norepinephrine and vanillylmandelic acid (VMA) levels were elevated in 90%, 80% and 90% of included patients. Open surgical excision of the mass was performed in 40%, transurethral resection in 8%, open radical prostatectomy in 24%, transurethral resection of the prostate in 16% and robot-assisted radical prostatectomy in 4% of included patients.

conclusionDue to atypical clinical manifestation and scarcity of prostatic paraganglioma, urologists should be aware of this extremely rare entity.

Indexed as

ParagangliomaProstatic NeoplasmsAdultAgedHumansMaleMiddle AgedneuroendocrineParagangliomapheochromocytomaprostatetumorurinary tract.

Identifiers

PMID38549519
OpenAlexW4393321940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.